この調査レポートでは、15か国（アメリカ、カナダ、ブラジル、ドイツ、イギリス、イタリア、フランス、スペイン、ロシア、スウェーデン、ポーランド、中国、日本、オーストラリア、サウジアラビア、インド）の詳細な分析が取り上げられています。さらに、この調査レポートには、ターゲット市場の機会、完全なパイプライン分析、市場プレーヤーの競合調査、投資機会、需要予測などのデータが示されています。また、成長指標、抑制要因、需給リスク、その他の重要な統計を評価するだけでなく、市場の進化に関連する現在および将来の市場動向の完全な評価も行っています。
1型糖尿病は、治療法の欠如によって特徴づけられる持続的な医学的疾患であり、インスリン療法などの既存の治療介入には固有の限界があります。より有効で作用時間の長い医薬品の開発が、医学的に必要であり、未解決の課題となっています。
1型糖尿病の細胞ベースの治療に関する臨床研究の数は着実に増加しています。肯定的な試験結果の達成は、市場の拡大を刺激し、医薬品の広範な受け入れと使用を促進する可能性があります。1型糖尿病と診断された人は、将来の治癒または病状の持続的な改善が期待できる代替治療アプローチの追求に積極的に取り組んでいます。
糖尿病の細胞療法の分野は、さまざまな政府機関や民間団体から多額の投資と資金を集めており、研究開発の取り組みが促進されています。食品医薬品局（FDA）や欧州医薬品庁 （EMA）などの規制機関は、細胞療法の研究者と協力する傾向を強めており、それによって進行と認可の手続きが迅速化されています。
1型糖尿病の治療に対する需要は旺盛で、この疾患と診断された人々の間で着実に増加しています。この慢性疾患を毎日維持することは、肉体的および精神的に多大な負担を課す可能性があります。細胞療法は持続可能な解決への有望な見通しを示しており、病状に苦しむ人々は、治療法をもたらす可能性のある新たな代替治療法の研究に熱心に取り組んでいます。
目次
Table of Contents
1. Introduction
1.1 Market Scope and Product Outlook
1.2 Executive Summary
2. Type 1 Diabetes Mellitus Background
2.1 Type 1 Diabetes Fact Sheet
2.2 Epidemiology
2.3 Causes and Risk Factors
2.4 Clinical Manifestations of Type I Diabetes
2.5 Diagnosis
2.6 Number of individuals with diabetes in each IDF Region, by age (2022)
2.7 Treatment Algorithm
2.8 Comparative Analysis of Cell Therapies vs Other Therapies for T1D
2.9 Approved Treatment: Landitra Overview
2.10 Number of individuals with diabetes in by top 20 countries, by age (2022)
3. Therapeutics in Pipeline
3.1 Emerging Cell Therapies in Pipeline
3.2 Emerging cell therapies in preclinical stages
3.3 Cell Therapies for Type I Diabetes Comparative Review
4. Pipeline Analysis, Assessment By Drug
4.1 VC01-103 - ViaCyte
4.1.1 Study Description
4.1.2 Endpoints
4.2 Stem Cell Educator (SCE) - Throne Biotechnologies Inc.
4.2.1 Study description
4.2.2 Endpoints
4.3 VC02-101 - ViaCyte
4.3.1 Study description
4.3.2 Endpoints
4.4 Autologous immunoregulatory dendritic cells (iDC) - DiaVacs, Inc.
4.4.1 Study Description
4.4.2 Endpoints
4.5 AVT001 - Avotres Inc.
4.5.1 Study Description
4.5.2 Endpoints
4.6 Human menstrual blood-derived MenSCs - S-Evans Biosciences Co., Ltd.
4.6.1 Study Description
4.6.2 Endpoints
4.7 PROCHYMAL® - Mesoblast, Inc.
4.7.1 Study Description
4.7.2 Endpoints
4.8 ProTrans - NextCell Pharma Ab
4.8.1 Study Description
4.8.2 Endpoints
4.9 VCTX211 - CRISPR Therapeutics AG
4.9.1 Study Description
4.9.2 Endpoints
4.10 Beta-Air - Beta-O2 Technologies
4.10.1 Study Description
4.10.2 Endpoints
4.11 VX-880 - Vertex Pharmaceuticals
4.11.1 Study Description
4.11.2 Endpoints
5. Type 1 Diabetes Landscape: Country Analysis
5.1 United States of America
5.1.1 Incidence of Type 1 Diabetes
5.1.2 Prevalence of Type 1 Diabetes
5.1.3 Target Market Opportunity, 2023-2030
5.2 Canada
5.2.1 Incidence of Type 1 Diabetes
5.2.2 Prevalence of Type 1 Diabetes
5.2.3 Target Market Opportunity, 2023-2030
5.3 Brazil
5.3.1 Incidence of Type 1 Diabetes
5.3.2 Prevalence of Type 1 Diabetes
5.3.3 Target Market Opportunity, 2023-2030
5.4 United Kingdom
5.4.1 Incidence of Type 1 Diabetes
5.4.2 Prevalence of Type 1 Diabetes
5.4.3 Target Market Opportunity, 2023-2030
5.5 Germany
5.5.1 Incidence of Type 1 Diabetes
5.5.2 Prevalence of Type 1 Diabetes
5.5.3 Target Market Opportunity, 2023-2030
5.6 France
5.6.1 Incidence of Type 1 Diabetes
5.6.2 Prevalence of Type 1 Diabetes
5.6.3 Target Market Opportunity, 2023-2030
5.7 Italy
5.7.1 Incidence of Type 1 Diabetes
5.7.2 Prevalence of Type 1 Diabetes
5.7.3 Target Market Opportunity, 2023-2030
5.8 Spain
5.8.1 Incidence of Type 1 Diabetes
5.8.2 Prevalence of Type 1 Diabetes
5.8.3 Target Market Opportunity, 2023-2030
5.9 Russia
5.9.1 Incidence of Type 1 Diabetes
5.9.2 Prevalence of Type 1 Diabetes
5.9.3 Target Market Opportunity, 2023-2030
5.10 Sweden
5.10.1 Incidence of Type 1 Diabetes
5.10.2 Prevalence of Type 1 Diabetes
5.10.3 Target Market Opportunity, 2023-2030
5.11 Poland
5.11.1 Incidence of Type 1 Diabetes
5.11.2 Prevalence of Type 1 Diabetes
5.11.3 Target Market Opportunity, 2023-2030
5.12 India
5.12.1 Incidence of Type 1 Diabetes
5.12.2 Prevalence of Type 1 Diabetes
5.12.3 Target Market Opportunity, 2023-2030
5.13 China
5.13.1 Incidence of Type 1 Diabetes
5.13.2 Prevalence of Type 1 Diabetes
5.13.3 Target Market Opportunity, 2023-2030
5.14 Australia
5.14.1 Incidence of Type 1 Diabetes
5.14.2 Prevalence of Type 1 Diabetes
5.14.3 Target Market Opportunity, 2023-2030
5.15 Saudi Arabia
5.15.1 Incidence of Type 1 Diabetes
5.15.2 Prevalence of Type 1 Diabetes
5.15.3 Target Market Opportunity, 2023-2030
6. Market Dynamics
6.1 Drivers
6.2 Restraints
6.3 Trends
7. Competitive Positioning
7.1 Market Position Matrix
7.2 Company profiles
7.2.1 Novo Nordisk
7.2.2 Sanofi
7.2.3 Vertex Pharmaceuticals
7.2.4 Sernova
7.2.5 Throne Biotechnologies
7.2.6 Kadimastem
7.2.7 CellTrans Inc.
7.2.8 Sigilon Therapeutics
7.2.9 Beta-O2
7.2.10 CRISPR Therapeutics AG
List of Figures
Figure 1: Estimated median Enteroviruses prevalence in different continents
Figure 2: Number of individuals with diabetes in each IDF Region, by age (2022)
Figure 3: Total Products by Phase
Figure 4: Incidence of Type 1 Diabetes in the United States, 2017-2019
Figure 5: Prevalence of Type 1 Diabetes in the United States, 2017-2019
Figure 6: United States of America Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 7: Incidence of Type 1 Diabetes in Canada, 2017-2019
Figure 8: Prevalence of Type 1 Diabetes in Canada, 2017-2019
Figure 9: Canada Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 10: Incidence of Type 1 Diabetes in Brazil, 2017-2019
Figure 11: Prevalence of Type 1 Diabetes in Brazil, 2017-2019
Figure 12: Brazil Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 13: Incidence of Type 1 Diabetes in the United Kingdom, 2017-2019
Figure 14: Prevalence of Type 1 Diabetes in the United Kingdom, 2017-2019
Figure 15: United Kingdom Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 16: Incidence of Type 1 Diabetes in Germany, 2017-2019
Figure 17: Prevalence of Type 1 Diabetes in Germany, 2017-2019
Figure 18: Germany Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 19: Incidence of Type 1 Diabetes in France, 2017-2019
Figure 20: Prevalence of Type 1 Diabetes in France, 2017-2019
Figure 21: France Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 22: Incidence of Type 1 Diabetes in Italy, 2017-2019
Figure 23: Prevalence of Type 1 Diabetes in Italy, 2017-2019
Figure 24: Italy Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 25: Incidence of Type 1 Diabetes in Spain, 2017-2019
Figure 26: Prevalence of Type 1 Diabetes in Spain, 2017-2019
Figure 27: Spain Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 28: Incidence of Type 1 Diabetes in Russia, 2017-2019
Figure 29: Prevalence of Type 1 Diabetes in Russia, 2017-2019
Figure 30: Russia Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 31: Incidence of Type 1 Diabetes in Sweden, 2017-2019
Figure 32: Prevalence of Type 1 Diabetes in Sweden, 2017-2019
Figure 33: Sweden Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 34: Incidence of Type 1 Diabetes in Poland, 2017-2019
Figure 35: Prevalence of Type 1 Diabetes in Poland, 2017-2019
Figure 36: Poland Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 37: Incidence of Type 1 Diabetes in India, 2017-2019
Figure 38: Prevalence of Type 1 Diabetes in India, 2017-2019
Figure 39: India Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 40: Incidence of Type 1 Diabetes in China, 2017-2019
Figure 41: Prevalence of Type 1 Diabetes in China, 2017-2019
Figure 42: China Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 43: Incidence of Type 1 Diabetes in Australia, 2017-2019
Figure 44: Prevalence of Type 1 Diabetes in Australia, 2017-2019
Figure 45: Australia Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 46: Incidence of Type 1 Diabetes in Saudi Arabia, 2017-2019
Figure 47: Prevalence of Type 1 Diabetes in Saudi Arabia, 2017-2019
Figure 48: Saudi Arabia Cell Therapies for Type 1 Diabetes Market Target Market Opportunity, 2023F-2030F (USD Million)
Figure 49: Global Impact of Drivers and Restraints
List of Tables
Table A1: Autoantibodies in Type 1 diabetes cases
Table A2: Diagnostic factors of T1D
Table A3: Drugs and their mode of action for T1D
Table A4: Number of individuals with diabetes by top 10 countries, by age (2022)
Table A5: Drugs in Type I Diabetes in pipeline
Table A6: Drugs in Type I Diabetes preclinical stages
